期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 387, 期 7, 页码 665-665出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMc2209237
关键词
-
The study confirmed that high-resolution anoscopy-guided periodic ablation of HSIL can reduce the risk of anal cancer in HIV-positive patients, but the reduction is small and of debatable clinical relevance.
To the Editor: The findings reported by Palefsky et al. (June 16 issue)(1) in the Anal Cancer-HSIL [high-grade squamous intraepithelial lesion] Outcomes Research (ANCHOR) trial provide proof of principle that high-resolution anoscopy-guided periodic ablation of HSIL reduces the risk of anal cancer among human immunodeficiency virus (HIV)-positive patients. However, the magnitude of this reduction was low, with a 48-month cumulative incidence of 0.9% in the intervention group and 1.8% in the control group. The between-group difference of approximately 0.2 percentage points per year is of debatable clinical relevance pending additional data on the disease stage and the treatment of and . . .
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据